Back to libraryGrowth Hormone

Ipamorelin

Research profile · How we handle evidence

Ipamorelin is a synthetic peptide studied as a selective growth-hormone secretagogue. It stimulates growth hormone release through ghrelin receptor signaling, and it’s often discussed for how GH pulses might affect recovery and metabolic markers.

Evidence Score

55/100

Preclinical signal

Category

Growth Hormone

Therapeutic area

Standard Dose

200-300mcg

1-3x daily (best before bed)

Half-life

~2 hr

Plasma elimination

Route

SC

Subcutaneous

Safety Tier

3

Limited data

Overview

In research, ipamorelin is used to nudge the body toward higher growth hormone release. It’s often described as more selective than older mixed GHRP compounds, but that doesn’t mean side effects are impossible. Human data is limited compared with standard hormone therapies, so treat it as an investigational research compound rather than a proven intervention.

Mechanism of Action

Selective ghrelin receptor agonist that stimulates growth hormone release from the pituitary without affecting cortisol or prolactin levels. Much cleaner profile than older GHRPs.

Selective Ghrelin Receptor (GHS R1a) Agonist With Minimal Cortisol Or Prolactin ReleaseStimulates Pulsatile GH Release That Preserves Natural Somatotroph RhythmIncreases IGF 1 Levels Without The Hunger Side Effects Of Other GHRPsPromotes Slow Wave Sleep Through GH Mediated Mechanisms

Benefits

  • Growth hormone release in preclinical and limited human research
  • Possible effects on recovery or body-composition markers are still being studied
  • Sleep and energy effects are reported anecdotally; human evidence is limited

Side Effects

  • Human safety data is limited; reported effects vary
  • Headache is a possible side effect
  • Fluid retention and appetite changes have been reported in some studies

Contraindications

  • Pregnant or breastfeeding women
  • Individuals under 18 years old
  • Those with known allergies to peptide components
  • Active cancer
  • Uncontrolled diabetes

Structure & Sequence

View 3D structure

Verified structure

Ipamorelin

Sequence illustration backed by PubChem match.

Verified via PubChemMatched by casNumber
C38H49N9O5711.85 DaCAS 170851-70-46 residues
Source: PubChemLookup: 170851-70-4InChIKey NEHWBYHLYZGBNO-BVEPWEIPSA-N
Amino Acid Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Weight
711.85 Da
Chemical Formula
C38H49N9O5
CAS Number
170851-70-4
InChIKey
NEHWBYHLYZGBNO-BVEPWEIPSA-N

Stack & Route Context

Stacks with

  • CJC-1295
  • GHRP-2
  • GHRP-6

Administration

Subcutaneous

Research Status

Research peptide for selective growth hormone release. Shows good safety profile in preclinical studies. Much cleaner than older GHRPs.

Approval Status

Preclinical

Sports Legal

Restricted

References

  1. 1

    Ipamorelin, the first selective growth hormone secretagogue

    1998

    View source
  2. 2

    Effects of ipamorelin on growth hormone release

    1999

    View source
  3. 3

    Safety and efficacy of ipamorelin in healthy adults

    2008

    View source

This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.

Research-driven insights.Evidence-based decisions.